Ionis Pharmaceuticals Inc. (IONS)

64.73
2.64 4.25
NASDAQ : Health Technology
Prev Close 62.09
Open 62.47
Day Low/High 62.46 / 65.06
52 Wk Low/High 40.91 / 86.58
Volume 1.11M
Avg Volume 1.42M
Exchange NASDAQ
Shares Outstanding 140.32M
Market Cap 8.96B
EPS 2.10
P/E Ratio 23.66
Div & Yield N.A. (N.A)

Latest News

Ionis Reports First Quarter 2019 Financial Results

Ionis Reports First Quarter 2019 Financial Results

Revenues more than doubled compared to 2018, resulting in net income of $84 million

Ionis Launches New Corporate Brand That Reflects Company's Industry-leading Innovation And Unique Culture Of Saying "yes" To Patients

Ionis Launches New Corporate Brand That Reflects Company's Industry-leading Innovation And Unique Culture Of Saying "yes" To Patients

CARLSBAD, Calif., May 6, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

Positive Clinical Data At AAN 2019 Reinforces Ionis' Commitment To Delivering Life-changing Medicines To Patients With Neurological Diseases

Positive Clinical Data At AAN 2019 Reinforces Ionis' Commitment To Delivering Life-changing Medicines To Patients With Neurological Diseases

Twelve presentations highlighting transformational medicines for SMA, hATTR, Huntington's disease, ALS, prion disease and others

Ionis Pharmaceuticals To Hold First Quarter 2019 Financial Results Webcast

Ionis Pharmaceuticals To Hold First Quarter 2019 Financial Results Webcast

Webcast scheduled for Thursday, May 9th at 11:30 a.m. Eastern Time

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

Ionis Pharmaceuticals To Provide Corporate Update At 2019 Annual Meeting Of Stockholders

Ionis Pharmaceuticals To Provide Corporate Update At 2019 Annual Meeting Of Stockholders

CARLSBAD, Calif., April 8, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

Ionis Announces Appointment Of Brett P. Monia Ph.D. To Its Board Of Directors

Ionis Announces Appointment Of Brett P. Monia Ph.D. To Its Board Of Directors

CARLSBAD, Calif., March 25, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals To Present At Upcoming Investor Conferences

Ionis Pharmaceuticals To Present At Upcoming Investor Conferences

CARLSBAD, Calif., March 7, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALRM, ATRS, CCK, CGC, FHN, FLGT, FND, GIFI, GTS, IMKTA, IONS, IROQ, LAWS, LEG, MANH, MOFG, NMFC, NPTN, NWN, RUN, VAC, WAL, XRAY Downgrades: ACHC, CNCE, HCI, ORBC, VMW Initiations: ALTR, FNKO, SE Read on to get TheStreet Quant Ratings' detailed report:

Ionis Exceeds 2018 Financial Guidance

Ionis Exceeds 2018 Financial Guidance

Total revenue increased 17% compared to 2017 to $600 million

Ionis Pharmaceuticals To Hold 2018 Financial Results Webcast

Ionis Pharmaceuticals To Hold 2018 Financial Results Webcast

Webcast scheduled for Wednesday, February 27 at 11:30 a.m. Eastern Time

How to Fatten Up Your Portfolio By Investing in the Obesity Epidemic

How to Fatten Up Your Portfolio By Investing in the Obesity Epidemic

As the U.S. and the world grow fatter, some investors are seeing green as they bulk up on stocks of companies on the front-lines of this 21st century Battle of the Bulge.

First Patient Enrolled In Pivotal Study Of RG6042 (IONIS-HTT Rx) For People With Huntington's Disease

First Patient Enrolled In Pivotal Study Of RG6042 (IONIS-HTT Rx) For People With Huntington's Disease

First of 4+ Ionis programs expected to advance to pivotal studies this year

Ionis Announces Plans For Management Transitions In 2020

Ionis Announces Plans For Management Transitions In 2020

CARLSBAD, Calif., Dec.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACIW, AEYE, HTA, IONS Downgrades: BCBP, DWSN, JAX, KORS Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Interesting IONS Put And Call Options For September 21st

Interesting IONS Put And Call Options For September 21st

Investors in Ionis Pharmaceuticals Inc saw new options become available this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IONS options chain for the new September 21st contracts and identified one put and one call contract of particular interest.

Ionis Pharmaceuticals Larger Than S&P 500 Component Leggett & Platt

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Ionis Pharmaceuticals Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example Leggett & Platt, Inc. , according to The Online Investor.

Alibaba, First American, Coherent: 'Mad Money' Lightning Round

Alibaba, First American, Coherent: 'Mad Money' Lightning Round

Jim Cramer makes the calls on Alibaba, First American, Coherent, Ionis Pharmacuetical, Skechers USA, Corning, Bank of Internet and more.

Where's the Real Leadership?: Cramer's 'Mad Money' Recap (Monday 4/30/18)

Where's the Real Leadership?: Cramer's 'Mad Money' Recap (Monday 4/30/18)

Love the banks, then hate the banks. Love the industrials? Nope, they're out, too. Jim Cramer says it's ugly, but he would use the weakness in the upside surprises.

Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases

Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases

Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced today they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological...

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.

New Data Presented At MDA Clinical Conference Show Benefit In Motor Function For Infants, Teens And Young Adults Treated With SPINRAZA® (nusinersen)

New Data Presented At MDA Clinical Conference Show Benefit In Motor Function For Infants, Teens And Young Adults Treated With SPINRAZA® (nusinersen)

Biogen (Nasdaq: BIIB) today announced new interim Phase 2 results from NURTURE, the ongoing open-label, single-arm study evaluating the efficacy and safety of SPINRAZA ® (nusinersen) among pre-symptomatic...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EOG, FGEN, GASS, GHC, SATS Downgrades: ALB, CFBK, CLI, DISCB, FORM, HCCI, IONS, KOP, LTC, MNRO, PNTR, SRE Initiations: FRAC, JELD, REVG Read on to get TheStreet Quant Ratings' detailed report:

Biogen And Ionis Enter Into New Collaboration To Identify Novel Therapies For The Treatment Of Spinal Muscular Atrophy

Biogen And Ionis Enter Into New Collaboration To Identify Novel Therapies For The Treatment Of Spinal Muscular Atrophy

Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that they have entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of...

The New England Journal Of Medicine Publishes First Phase 3 Study Results Of SPINRAZA® For The Treatment Of Spinal Muscular Atrophy

The New England Journal Of Medicine Publishes First Phase 3 Study Results Of SPINRAZA® For The Treatment Of Spinal Muscular Atrophy

Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the end of study results from ENDEAR, the Phase 3 study of SPINRAZA ® (nusinersen) for the treatment of spinal muscular atrophy...

Noteworthy Tuesday Option Activity: IONS, PTCT, WAB

Noteworthy Tuesday Option Activity: IONS, PTCT, WAB

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ionis Pharmaceuticals Inc , where a total of 10,049 contracts have traded so far, representing approximately 1.0 million underlying shares. That amounts to about 75.1% of IONS's average daily trading volume over the past month of 1.3 million shares.

TheStreet Quant Rating: B- (Buy)